公开(公告)号：EP3223821A1

公开(公告)日：2017-10-04

申请号：EP15797685.3

申请日：2015-11-23

申请人： Bayer Pharma Aktiengesellschaft

发明人： SCHALL, Andreas ,  KLAR, Jürgen ,  LOBELL, Mario ,  SCHIROK, Hartmut ,  TELSER, Joachim ,  MÜLLER, Steffen ,  BROHM, Dirk ,  BRIEM, Hans ,  JÖRISSEN, Hannah ,  BÖTTGER, Michael ,  DEGENFELD VON, Georges ,  SCHLANGE, Thomas ,  BÖMER, Ulf ,  LINDNER, Niels ,  EILKEN, Hanna ,  HRISTODOROV, Dmitrij ,  WASNAIRE, Pierre ,  GERICKE, Kersten Matthias ,  BÄRFACKER, Lars

IPC分类号： A61K31/5513 ,  A61P27/02 ,  C07D487/04 ,  A61P35/00

CPC分类号： C07D487/04 ,  A61K31/5513 ,  A61K39/39558

摘要： The invention relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-
b ]-[1,5]benzodiazepine-5-one-derivatives, to methods for the production thereof, use thereof alone or in combination for treating and/or for preventing diseases and use thereof in producing medicaments for treating and/or preventing diseases, especially angiogenic disorders and hyperproliferative disorders with a neovascularization component, such as opthalmologic disorders such as cancers and tumor diseases. Such treatments can be carried out as monotherapy or also in combination with other medicaments or additional therapeutic measures.

摘要翻译： 本申请涉及新的（3-羟基苯基）氨基取代的吡啶并[2,3-b] [1,5]苯并二氮杂-5-酮衍生物，涉及其制备方法，其单独或组合用于治疗 和/或预防疾病及其用于制备用于治疗和/或预防疾病，尤其是新生血管形成起作用的血管生成病症和过度增殖性疾病（例如眼科疾病和癌症和肿瘤）的药物的用途。 这些治疗可以作为单一疗法或者与其他药物或其他治疗措施组合进行。